Terrisse S, Karamouza E, Parker CC, et al. - In this meta-analysis, experts evaluated OS in men with bone metastases from castration-resistant prostate cancer (CRPC) treated with bone-targeted radioisotopes (RIs) and contrasted the impacts of α-emitting RIs with β-emitting RIs. There were six randomized clinical trials comprising of 2,081 individuals that were reviewed. In metastatic CRPC, a notable advancement of OS and symptomatic skeletal event-free survival with bone-targeted α-emitting was noted, however, not β-emitting RIs. Thus, provided the between-trial heterogeneity, provided the between-trial heterogeneity.